Literature DB >> 12655105

In vitro cell-free conversion of bacterial recombinant PrP to PrPres as a model for conversion.

Louise Kirby1, Christopher R Birkett1, Helene Rudyk2, Ian H Gilbert2, James Hope1.   

Abstract

Prion diseases are associated with the conversion of the normal cellular prion protein, PrP(C), to the abnormal disease-associated protein, PrP(Sc). This conversion can be mimicked in vitro using PrP(Sc) isolated from the brains of scrapie-infected animals to induce conversion of recombinant PrP(C) into a proteinase K-resistant isoform, PrP(res). Traditionally, the 'cell-free' conversion assay has used, as substrate, recombinant PrP(C) purified from mammalian tissue culture cells or, more recently, from baculovirus-infected insect cells. The cell-free conversion assay has been modified by replacing the tissue culture-derived PrP(C) with recombinant PrP purified from bacteria. Bacterial expression and chromatographic purification give high yields of recombinant radiolabelled untagged protein, eliminates artefacts that may be due to cellular factors or antibody fragments normally present in labelled PrP preparations and allows accurate and rapid variation of protein sequence using standard molecular biological techniques. In addition, these cell-free conversion assays were carried out under more physiological conditions, giving more relevance to the assay as a model for conversion. To validate its use in this assay, this bacterial recombinant PrP has been shown to have the conversion properties of mammalian PrP(C): (i) it converts to a proteinase K-resistant isoform in the presence of PrP(Sc); (ii) the efficiency of this conversion by PrP(Sc) of different strains and species parallels that found in vivo; and (iii) its cell-free conversion is inhibited by Congo Red analogues in a structure-dependent manner similar to that seen in in vivo and in vitro cell assays.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12655105     DOI: 10.1099/vir.0.18903-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  20 in total

1.  Proper calibration of ultrasonic power enabled the quantitative analysis of the ultrasonication-induced amyloid formation process.

Authors:  Kei-ichi Yamaguchi; Tomoharu Matsumoto; Kazuo Kuwata
Journal:  Protein Sci       Date:  2011-11-22       Impact factor: 6.725

Review 2.  Structural requirements for efficient prion protein conversion: cofactors may promote a conversion-competent structure for PrP(C).

Authors:  Andrew C Gill; Sonya Agarwal; Teresa J T Pinheiro; James F Graham
Journal:  Prion       Date:  2010-10-20       Impact factor: 3.931

3.  Low density subcellular fractions enhance disease-specific prion protein misfolding.

Authors:  James F Graham; Sonya Agarwal; Dominic Kurian; Louise Kirby; Teresa J T Pinheiro; Andrew C Gill
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

Review 4.  Formation and properties of amyloid fibrils of prion protein.

Authors:  Kei-Ichi Yamaguchi; Kazuo Kuwata
Journal:  Biophys Rev       Date:  2017-12-04

5.  In vitro amplification of scrapie and chronic wasting disease PrP(res) using baculovirus-expressed recombinant PrP as substrate.

Authors:  Bonto Faburay; Dongseob Tark; Anumantha G Kanthasamy; Juergen A Richt
Journal:  Prion       Date:  2014       Impact factor: 3.931

6.  Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins.

Authors:  Jihoon Kim; Masaki Kobayashi; Makoto Fukuda; Daisuke Ogasawara; Natsuki Kobayashi; Sungwoong Han; Chikashi Nakamura; Masaki Inada; Chisato Miyaura; Kazunori Ikebukuro; Koji Sode
Journal:  Prion       Date:  2010-01-04       Impact factor: 3.931

Review 7.  The role of the prion protein membrane anchor in prion infection.

Authors:  Suzette A Priola; Kristin L McNally
Journal:  Prion       Date:  2009-07-07       Impact factor: 3.931

8.  The role of glycophosphatidylinositol anchor in the amplification of the scrapie isoform of prion protein in vitro.

Authors:  Jae-Il Kim; Krystyna Surewicz; Pierluigi Gambetti; Witold K Surewicz
Journal:  FEBS Lett       Date:  2009-10-23       Impact factor: 4.124

Review 9.  Recent advances in prion chemotherapeutics.

Authors:  Valerie L Sim; Byron Caughey
Journal:  Infect Disord Drug Targets       Date:  2009-02

10.  Mechanistic insights into the cure of prion disease by novel antiprion compounds.

Authors:  Sarah Webb; Tamuna Lekishvili; Corinna Loeschner; Shane Sellarajah; Frances Prelli; Thomas Wisniewski; Ian H Gilbert; David R Brown
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.